Literature DB >> 28288718

Splenic marginal zone lymphoma.

Miguel A Piris1, Arantza Onaindía2, Manuela Mollejo3.   

Abstract

Splenic marginal zone lymphoma (SMZL) is an indolent small B-cell lymphoma involving the spleen and bone marrow characterized by a micronodular tumoral infiltration that replaces the preexisting lymphoid follicles and shows marginal zone differentiation as a distinctive finding. SMZL cases are characterized by prominent splenomegaly and bone marrow and peripheral blood infiltration. Cells in peripheral blood show a villous cytology. Bone marrow and peripheral blood characteristic features usually allow a diagnosis of SMZL to be performed. Mutational spectrum of SMZL identifies specific findings, such as 7q loss and NOTCH2 and KLF2 mutations, both genes related with marginal zone differentiation. There is a striking clinical variability in SMZL cases, dependent of the tumoral load and performance status. Specific molecular markers such as 7q loss, p53 loss/mutation, NOTCH2 and KLF2 mutations have been found to be associated with the clinical variability. Distinction from Monoclonal B-cell lymphocytosis with marginal zone phenotype is still an open issue that requires identification of precise and specific thresholds with clinical meaning.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Marginal zone; Monoclonal B-cell lymphocytosis; NOTCH2/KLF2; Splenic lymphoma

Mesh:

Substances:

Year:  2016        PMID: 28288718     DOI: 10.1016/j.beha.2016.09.005

Source DB:  PubMed          Journal:  Best Pract Res Clin Haematol        ISSN: 1521-6926            Impact factor:   3.020


  7 in total

1.  A unique bone marrow lymphoma patient presenting with an isolated mass: A case report.

Authors:  Yi-Wen Xu; Ming-Hui Duan
Journal:  Oncol Lett       Date:  2017-12-06       Impact factor: 2.967

2.  Distinction of lymphoid and myeloid clonal hematopoiesis.

Authors:  Abhishek Niroula; Aswin Sekar; Mark A Murakami; Mark Trinder; Mridul Agrawal; Waihay J Wong; Alexander G Bick; Md Mesbah Uddin; Christopher J Gibson; Gabriel K Griffin; Michael C Honigberg; Seyedeh M Zekavat; Kaavya Paruchuri; Pradeep Natarajan; Benjamin L Ebert
Journal:  Nat Med       Date:  2021-10-18       Impact factor: 53.440

3.  Clinico-biological features and outcome of patients with splenic marginal zone lymphoma with histological transformation.

Authors:  Gabriela Bastidas-Mora; Sílvia Beà; Alba Navarro; Eva Gine; Dolors Costa; Julio Delgado; Tycho Baumann; Laura Magnano; Alfredo Rivas-Delgado; Neus Villamor; Dolors Colomer; Mónica Lopez-Guerra; María Rozman; Olga Balagué; Daniel Martínez; Maria Joao Baptista; Lourdes Escoda; Miguel Alcoceba; Margarita Blanes; Fina Climent; Elías Campo; Andrew Wotherspoon; Armando López-Guillermo; Estella Matutes
Journal:  Br J Haematol       Date:  2021-09-14       Impact factor: 8.615

4.  Marginal zone lymphoma: present status and future perspectives.

Authors:  Chan Y Cheah; Emanuele Zucca; Davide Rossi; Thomas M Habermann
Journal:  Haematologica       Date:  2022-01-01       Impact factor: 9.941

5.  The effect of surgery on primary splenic lymphoma: A study based on SEER database.

Authors:  Xiaotao Pan; Dongfeng Ren; Ya Li; Jin Zhao
Journal:  Cancer Med       Date:  2021-09-21       Impact factor: 4.452

6.  Notch dimerization and gene dosage are important for normal heart development, intestinal stem cell maintenance, and splenic marginal zone B-cell homeostasis during mite infestation.

Authors:  Francis M Kobia; Kristina Preusse; Quanhui Dai; Nicholas Weaver; Matthew R Hass; Praneet Chaturvedi; Sarah J Stein; Warren S Pear; Zhenyu Yuan; Rhett A Kovall; Yi Kuang; Natanel Eafergen; David Sprinzak; Brian Gebelein; Eric W Brunskill; Raphael Kopan
Journal:  PLoS Biol       Date:  2020-10-05       Impact factor: 8.029

Review 7.  CD5-Negative, CD10-Negative Low-Grade B-Cell Lymphoproliferative Disorders of the Spleen.

Authors:  John J Schmieg; Jeannie M Muir; Nadine S Aguilera; Aaron Auerbach
Journal:  Curr Oncol       Date:  2021-12-04       Impact factor: 3.677

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.